Survey
Quarterly Survey: Demodex blepharitis and the potential of Tarsus' XDEMVY January 2024
Ticker(s): TARSThe survey included 20 healthcare experts including Optometrists and general eye doctors
How many patients with Demodex blepharitis do you have under your care?
How would you best describe your practice?
- Academic
- Community
- Commercial
- Private
- Other
How many patients with Demodex blepharitis are eligible for Xdemvy (lotilaner ophthalmic solution)?
How effective are each of the following treatments in treating Demodex blepharitis?
- Eyelid hygiene and warm compresses
- Topical antibiotics
- Oral medications
- Tea tree oil-based products
Which treatment do you primarily use for Demodex blepharitis? Select one.
- Eyelid hygiene and warm compresses
- Tea tree oil-based products
- Topical antibiotics
- Oral medications
- Other
What is your view on Xdemvy (lotilaner ophthalmic solution) as a treatment option for Demodex blepharitis?
With the current data in consideration, how would you rate Xdemvy (lotilaner ophthalmic solution) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
How will cost specifically impact access to Xdemvy (lotilaner ophthalmic solution) for patients with Demodex blepharitis?
- No impact
- Minor impact
- Moderate impact
- Significant impact
- I am not sure
In your opinion, how does Xdemvy (lotilaner ophthalmic solution) compare to other Demodex blepharitis treatment options? Please be specific.
What line of treatment would you consider Xdemvy (lotilaner ophthalmic solution) for patients with Demodex blepharitis?
What percent % of your patients with Demodex blepharitis do you expect to be Xdemvy (lotilaner ophthalmic solution) at the following time points?
- March 31,2024
- In 1 year
- In 3 years
- In 5 years
Do you think that Xdemvy (lotilaner ophthalmic solution) will grow the market for Demodex blepharitis treatments?
- Yes
- No
- Not Sure
Why or why not? Please be specific.
On a scale of 1-10 (where 1 is low and 10 is high) how excited are you for Xdemvy (lotilaner ophthalmic solution) in treating Demodex blepharitis?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
